Fixed-dose Combination Antihypertensives and Risk of Medication Errors

Overview

Journal Heart

Date 2018 Aug 4

PMID 30072364

Citations 9

Authors

Frank Moriarty

Kathleen Bennett

Tom Fahey

Affiliations

Soon will be listed here.

Abstract

Objective: While fixed-dose combinations (FDC) can improve adherence, they may add complexity to the prescribing/dispensing process, potentially increasing risk of medication errors. This study aimed to determine if prescriptions for antihypertensive FDCs increase the risk of therapeutic duplication and drug-drug interactions (DDI).

Methods: This retrospective observational study used administrative pharmacy claims data from the Irish Primary Care Reimbursement Service. Prescriptions dispensed to adults in 2015 were included if they contained an antihypertensive FDC, or the same drugs prescribed separately. The outcomes were therapeutic duplication and potentially serious DDI involving FDC drugs. Relative risk (RR) of these outcomes, adjusted for prescription and patient factors, was determined using generalised linear models with Poisson distributions and propensity score matching.

Results: This study included 307 833 FDC prescriptions (67.0%) and 151 632 separate component prescriptions. Half of patients prescribed FDCs were female with a mean age of 67.1 (SD 12.5) years and, compared with separate component prescriptions, FDCs were less often coprescribed with other cardiovascular medications. Therapeutic duplication occurred in 0.8% of prescriptions, most often involving calcium channel blockers, and 10.6% contained a DDI (most often amlodipine and simvastatin). The RR of therapeutic duplication on FDC prescriptions compared with separate component prescriptions was 1.46 (95% CI 1.17 to 1.83) and the adjusted RR was 2.06 (95% CI 1.64 to 2.60). For DDIs, there was no significant difference between FDC and separate component prescriptions after confounder adjustment.

Conclusions: This study found FDCs were associated with increased risk of duplication. When considering prescribing FDCs, this safety consideration should be weighed against potential benefits.

Citing Articles

Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) scientific statement on the simplification of the drug regimen for secondary cardiovascular prevention.

De Luca L, Di Fusco S, Iannopollo G, Mistrulli R, Rizzello V, Aimo A Eur Heart J Suppl. 2024; 26(Suppl 2):ii236-ii251.

PMID: 38784670 PMC: 11110452. DOI: 10.1093/eurheartjsupp/suae032.

Barriers and Facilitators of Medication Adherence in Hypertension Patients: A Meta-Integration of Qualitative Research.

Zhou X, Zhang X, Gu N, Cai W, Feng J J Patient Exp. 2024; 11:23743735241241176.

PMID: 38549805 PMC: 10976505. DOI: 10.1177/23743735241241176.

Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up.

Kalinic D, Skrbic R, Vulic D, Stojakovic N, Stoisavljevic-Satara S, Stojiljkovic M Front Pharmacol. 2022; 13:889047.

PMID: 35784727 PMC: 9240340. DOI: 10.3389/fphar.2022.889047.

The feasibility of polypill for cardiovascular disease prevention in Asian Population.

Sukonthasarn A, Chia Y, Wang J, Nailes J, Buranakitjaroen P, Van Minh H J Clin Hypertens (Greenwich). 2020; 23(3):545-555.

PMID: 33086429 PMC: 8029502. DOI: 10.1111/jch.14075.

Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost.

Salam A, Huffman M, Kanukula R, Hari Prasad E, Sharma A, Heller D J Clin Hypertens (Greenwich). 2020; 22(10):1769-1779.

PMID: 32815663 PMC: 8030031. DOI: 10.1111/jch.14009.

References

Barnett K, Mercer S, Norbury M, Watt G, Wyke S, Guthrie B . Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012; 380(9836):37-43. DOI: 10.1016/S0140-6736(12)60240-2. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4(10):e296. PMC: 2020495. DOI: 10.1371/journal.pmed.0040296. View

Schneeweiss S . Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006; 15(5):291-303. DOI: 10.1002/pds.1200. View

Garjon J, Saiz L, Azparren A, Elizondo J, Gaminde I, Ariz M . First-line combination therapy versus first-line monotherapy for primary hypertension. Cochrane Database Syst Rev. 2017; 1:CD010316. PMC: 6464906. DOI: 10.1002/14651858.CD010316.pub2. View

Bahiru E, de Cates A, Farr M, Jarvis M, Palla M, Rees K . Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017; 3:CD009868. PMC: 6464321. DOI: 10.1002/14651858.CD009868.pub3. View

Huffman M, Xavier D, Perel P . Uses of polypills for cardiovascular disease and evidence to date. Lancet. 2017; 389(10073):1055-1065. DOI: 10.1016/S0140-6736(17)30553-6. View

Sinnott S, Bennett K, Cahir C . Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data. Eur J Clin Pharmacol. 2017; 73(11):1449-1455. PMC: 5662670. DOI: 10.1007/s00228-017-2310-7. View

Webster R, Castellano J, Onuma O . Putting polypills into practice: challenges and lessons learned. Lancet. 2017; 389(10073):1066-1074. DOI: 10.1016/S0140-6736(17)30558-5. View

Garcia B, Elenjord R, Bjornstad C, Halvorsen K, Hortemo S, Madsen S . Safety and efficiency of a new generic package labelling: a before and after study in a simulated setting. BMJ Qual Saf. 2017; 26(10):817-823. PMC: 5739837. DOI: 10.1136/bmjqs-2016-006422. View

10.

Aronson J . Medication errors: what they are, how they happen, and how to avoid them. QJM. 2009; 102(8):513-21. DOI: 10.1093/qjmed/hcp052. View

11.

Gradman A, Basile J, Carter B, Bakris G, Materson B, Black H . Combination therapy in hypertension. J Am Soc Hypertens. 2010; 4(2):90-8. DOI: 10.1016/j.jash.2010.03.001. View

12.

Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J . Modelling the expected net benefits of interventions to reduce the burden of medication errors. J Health Serv Res Policy. 2008; 13(2):85-91. DOI: 10.1258/jhsrp.2007.007011. View

13.

Berman A . Reducing medication errors through naming, labeling, and packaging. J Med Syst. 2004; 28(1):9-29. DOI: 10.1023/b:joms.0000021518.60670.10. View

14.

Hess G, Hill J, Lau H, Dastani H, Chaudhari P . Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy. P T. 2009; 33(11):652-66. PMC: 2730815. View

15.

Wolfstadt J, Gurwitz J, Field T, Lee M, Kalkar S, Wu W . The effect of computerized physician order entry with clinical decision support on the rates of adverse drug events: a systematic review. J Gen Intern Med. 2008; 23(4):451-8. PMC: 2359507. DOI: 10.1007/s11606-008-0504-5. View

16.

Austin P . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010; 10(2):150-61. PMC: 3120982. DOI: 10.1002/pst.433. View

17.

Aronson J . Medication errors resulting from the confusion of drug names. Expert Opin Drug Saf. 2004; 3(3):167-72. DOI: 10.1517/eods.3.3.167.31069. View

18.

Hao J, Rodriguez-Monguio R, Seoane-Vazquez E . Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals. PLoS One. 2015; 10(10):e0140708. PMC: 4607470. DOI: 10.1371/journal.pone.0140708. View

19.

Farrell B, Merkley V, Ingar N . Reducing pill burden and helping with medication awareness to improve adherence. Can Pharm J (Ott). 2013; 146(5):262-9. PMC: 3785195. DOI: 10.1177/1715163513500208. View

20.

Alldred D, Standage C, Fletcher O, Savage I, Carpenter J, Barber N . The influence of formulation and medicine delivery system on medication administration errors in care homes for older people. BMJ Qual Saf. 2011; 20(5):397-401. DOI: 10.1136/bmjqs.2010.046318. View